Rigel Pharmaceuticals (RIGL)
Commercializes specialty treatments for a blood disorder, a leukemia, and RET-fusion cancers in the US.
Something off on this page? Send us feedback.
Sells three FDA-approved specialty drugs in the United States — a self-discovered chronic ITP treatment, an in-licensed acute myeloid leukemia therapy, and an acquired RET-fusion lung and thyroid cancer treatment — while licensing international marketing rights to partners in Europe and Asia rather than commercializing abroad directly.
Commercializes three specialty drugs in the United States after two decades as a discovery-stage kinase-biology company: TAVALISSE, an internally discovered treatment for chronic immune thrombocytopenia; REZLIDHIA, an in-licensed therapy for IDH1-mutated relapsed or refractory acute myeloid leukemia; and GAVRETO, an acquired treatment for RET-fusion lung and thyroid cancers.
International rights are licensed to partners rather than held directly: Grifols markets fostamatinib in Europe, and Kissei sublicenses olutasidenib across Japan and parts of Asia. The company operates as a single reportable segment centered on US commercialization.
TAVALISSE remains the largest contributor to product revenue. Its underlying compound has also failed several late-stage trials outside chronic ITP, including autoimmune hemolytic anemia and hospitalized COVID-19, leaving its approved use concentrated in the original indication.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | Reiterate | Rating: —Target: $2 | Target: $49 |
| Aug 14, 2026 | H.C. Wainwright | Reiterate | Rating: —Target: — | Target: $85 |
| Nov 5, 2025 | Jefferies | Upgrade | Target: $1 | Target: $42 |
| Nov 5, 2025 | Cantor Fitzgerald | Reiterate | Rating: —Target: — | Target: $38 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $95.3M · Total debt $40.0M · Total assets $521.1M · Shareholders' equity $425.4M
- Revenue
- $78.7M
- Operating income
- $23.6M
- Net income
- $17.3M
No dividends on record.
| Institutions | 88.54% | 16.54M shares | |
|---|---|---|---|
| 161 holders · as of Jun 30, 2026 | |||
| Insiders | 3.30% | 615.6K shares | |
| 12 holders · as of Sep 3, 2026 | |||
| Other | 8.16% | 1.53M shares | |
| remainder | |||
18.68M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 10.38% | 1.94M | as of Jun 30, 2026 |
Soleus Capital Management, L.P.Institution | 9.87% | 1.84M | as of Jun 30, 2026 |
Armistice Capital, LLCInstitution | 8.95% | 1.67M | as of Jun 30, 2026 |
State Street CorpInstitution | 5.57% | 1.04M | as of Jun 30, 2026 |
Soleus Capital Master Fund, L.P.Institution | 5.18% | 968,108 | filed May 7, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jun 22, 2026 | Kamil Ali-Jackson | director | −2,500 | $35.00 |
| May 26, 2026 | Kamil Ali-Jackson | director | −2,500 | $29.17 |
| Feb 20, 2026 | Walter H. Moos | director | −4,000 | $36.36 |
- Eli Lilly
Dominant first-mover rival in RET-fusion NSCLC and thyroid cancer.
- Amgen
Head-to-head TPO-RA rival in chronic ITP.
- Novartis (ADR)
Dominant oral TPO-RA rival in chronic ITP.
- Sanofi (ADR)
First-in-class BTK inhibitor rival newly approved in chronic ITP.
- AbbVie
Frontline AML combination backbone shaping later-line treatment choices.
- argenx (ADR)
Emerging ITP pipeline threat; approved for ITP only in Japan so far.
- Bristol-Myers Squibb
Adjacent IDH2-mutant AML rival within the same IDH-inhibitor class.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rigel Pharmaceuticals | $48.82 | +0.03% | $871.3M | 2.9 | 14.5 | 3.1 | −22.6% |
| Eli Lilly | $1,172.96 | +0.21% | $1.10T | 39.1 | 28.6 | 13.8 | +47.7% |
| Amgen | $410.00 | −0.05% | $212.19B | 24.4 | 17.5 | 5.6 | +9.7% |
| Novartis (ADR) | $141.28 | +0.01% | $267.96B | 21.3 | 15.0 | 4.8 | +0.9% |
| Sanofi (ADR) | $42.49 | +0.05% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| AbbVie | $265.21 | −0.02% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| argenx (ADR) | $963.79 | −0.02% | $61.45B | 37.7 | — | 10.2 | +197.0% |
| Bristol-Myers Squibb | $62.31 | +0.10% | $127.91B | 13.8 | 9.7 | 2.6 | +5.7% |
| Median | 37.7 | 17.5 | 5.6 | +10.2% |